Document is current

Article History

Received: 23 July 2025

Revised: 19 September 2025

Accepted: 21 September 2025

First Online: 11 October 2025

Change Date: 24 November 2025

Change Type: Update

Change Details: Formatting changes in the table 2 i.e. indent “Headache” word to the same extent as 'COVID-19' have been done.

Declarations

:

: V. Bril is a consultant for Akcea, Alexion Pharmaceuticals, Alnylam, argenx, CSL, Grifols, Immunovant, Ionis, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Momenta (now Johnson & Johnson), Novo Nordisk, Octapharma, Pfizer, Powell Mansfield, Roche, Sanofi, Takeda Pharmaceuticals and UCB. She has received research support from Akcea, Alexion Pharmaceuticals, argenx, CSL, Grifols, Immunovant, Ionis, Momenta (now Johnson & Johnson), Octapharma, Takeda Pharmaceuticals, UCB and Viela Bio (now Amgen). C. Antozzi has received funding for congress and Institutional Review Board participation from Alexion Pharmaceuticals, argenx, Biogen, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Momenta (now Johnson & Johnson) and UCB. T. Berkowicz has nothing to disclose. A. Drużdż has nothing to disclose. R.K. Gandhi Mehta has received research funding from Akcea Pharmaceuticals (now AstraZeneca), EMD Serono, Novartis and UCB. She has served on advisory boards for Amgen and UCB and has received speaker honoraria from UCB. Z.K. Mahuwala has received compensation for advisory board participation from Alexion Pharmaceuticals and Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine) and has served as a panellist for Academic CME. She has received research funding for clinical trials paid to the University of Kentucky from Alexion Pharmaceuticals, argenx, Immunovant, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), RemeGen Biosciences and UCB. J. Zschüntzsch has been awarded research grants from the German Innovationfond, German Society for Muscle Disease (DGM), and the Innovative Medicines Initiative 2 Joint Undertaking (IMI JU) of the European Commission (Grant Number: 101034427-2). She has received speaker honoraria or travel grants from Alexion, argenx, Kedrion, Roche and Sanofi. She serves on scientific or educational advisory boards for Alexion, Amicus, argenx, iThera, Kedrion, Sanofi, and UCB. She has received research support from argenx and UCB. She is a member of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD) and a member of the medical advisory boards of the DGM and the German Myasthenia Gravis Society. M. Boehnlein is an employee and shareholder of UCB. V. Kerbusch is a paid Consultant for UCB. A. Lavrov is an employee and shareholder of UCB. M. Morris is an employee and shareholder of UCB. P. Singh is an employee and shareholder of UCB, and is a previous employee and shareholder of GSK. M.I. Leite is funded by the NHS (Myasthenia and Related Disorders Service and National Specialised Commissioning Group for Neuromyelitis Optica, UK) and by the University of Oxford, UK. She has been awarded research grants from UK associations for patients with myasthenia and with muscular disorders (Myaware and Muscular Dystrophy UK, respectively) and the University of Oxford. She has received speaker honoraria or travel grants from Biogen, the Guthy-Jackson Charitable Foundation, Novartis and UCB. She serves on scientific or educational advisory boards for argenx, Horizon Therapeutics (now Amgen) and UCB.

: Study protocol, amendments, and study participant informed consent were approved by a national, regional or independent ethics committee or institutional review board. All patients provided the written informed consent. This study was conducted in accordance with local regulations, International Conference on Harmonization Good Clinical Practice requirements, and the principles of the Declaration of Helsinki.